Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of enzomenib, an investigational, oral selective menin inhibitor being researched for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback